Resources

Categories
  1. An easy prescription guideline

    In order to help you expedite the request process with us, we put together a quick prescription guideline.

    Read more »
  2. What is Tudca? | Information & Faq | TheSocialMedwork

    News update5 common questions about the supplement that may be useful for ALS, Parkinson's and Alzheimers.

    Read more »
  3. Promising new data analysis for Alzheimer’s disease treatment

    New analysis of Biogen’s aducanumab shows reduction in clinical decline in Alzheimer’s disease.

    Xray of human brain

    Read more »
  4. How to spot a scam website

    As a pioneer of a completely new type of global service, we understand that trust, security and credibility are paramount–especially when paying for medicines which are essential and often the only treatment option available. There are an increasing number of scam websites and we ourselves have been the subject of one such scam. In this article we’ll give you tips on how to spot these fakers.

    online scam

    Read more »
  5. Matt's story: I'm doing fine

    I’m lucky. It's been 4 years since the first MND symptoms, only my voice has been impacted.

    matt 2x

    Read more »
  6. David's story: Nothing to lose

    Two and a half years after his diagnosis, David found a medicine with off-label application for MND.

    david 2x

    Read more »
  7. New Parkinson's therapy approved by the FDA

    Kyowa Hakko Kirin's Parkinson's therapy, Nourianz (istradefylline), gains FDA approval as an add-on to levodopa/carbidopa.

    US flag thumbs up gesture

    Read more »
  8. China approves edaravone for ALS

    Radicut/Radicava (edaravone), shown to slow the progression of ALS, is now approved for patients in China.

    China flag thumbs-uo hand gesture

    Read more »
  9. SMC rejects two cystic fibrosis drugs

    Orkambi and Symkevi have been rejected by the Scotland Medicines Consortium (SMC) due to their conclusion that the costs outweigh the benefits.

    red haired girl on oxygen

    Read more »
  10. EMA recommends approval of Vitrakvi (larotrectinib)

    Vitrakvi (larotrectinib) recommended by the CHMP for approval in the EU.

    EU approval OK hand gesture

    Read more »
  11. Fiona's story: PBC, my mother and me

    fiona 2xAfter 40 years with primary biliary cholangitis, Fiona's mother is still alive thanks to her daughter's dedication and a liver transplant.

    Read more »
  12. Marc's story: A brief look at life with ALS in the US

    After 3 years of living with ALS, Marc found a new medicine on the other side of the world. 

    marc 2x

    Read more »
  13. Mark & Dee's story: For better, not worse

    With tears, laughter and hope, Mark and his family find their own way to cope with ALS.

    mark and dee 2x

    Read more »
  14. Peter's story: Life goes on

    Diagnosed with ALS only 6 months ago, Peter went against the current to find more options to treat his disease.

    peter golfing close

    Read more »
  15. MN-166 (ibudilast) to enter phase III clinical trials for progressive MS

    MN-166 (ibudilast) will be part of the Phase III clinical trial on progressive multiple sclerosis subjects with secondary progressive MS without relapses. 

    pipette samples

    Read more »